Robuta

https://www.mdpi.com/2077-0383/12/16/5252
Dinutuximab beta is approved for the maintenance treatment of patients with high-risk neuroblastoma (HR-NB), including patients with relapsed/refractory (R/R)...
dinutuximab betamaintenance therapyhigh riskpatientsneuroblastoma